Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

248.68 +1.17 (+0.47%)

Official Closing Price Updated: 4:15 PM EDT, Sep 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Via Investor's Business Daily

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Uncovering Potential: Alnylam Pharmaceuticals's Earnings Preview ↗

October 29, 2025

Via Benzinga

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗

October 27, 2025

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.

Via Benzinga

Peering Into Alnylam Pharmaceuticals Inc's Recent Short Interest ↗

October 21, 2025

Via Benzinga

$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗

October 14, 2025

Via Benzinga

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

October 11, 2025

The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the potential catalysts driving attention.

Via Benzinga

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout ↗

October 07, 2025

Alnylam Pharmaceuticals (ALNY) presents a strong technical breakout setup with a high rating for both trend momentum and consolidation quality.

Via Chartmill

27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know ↗

October 06, 2025

Via Benzinga

Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape

September 30, 2025

September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between...

Via MarketMinute

$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

September 26, 2025

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam...

Via Benzinga

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug ↗

September 25, 2025

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary...

Via Benzinga

Beyond The Numbers: 28 Analysts Discuss Alnylam Pharmaceuticals Stock ↗

September 19, 2025

Via Benzinga

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

September 08, 2025

Via Benzinga

$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

September 02, 2025

Via Benzinga

Where Alnylam Pharmaceuticals Stands With Analysts ↗

September 02, 2025

Via Benzinga

A Closer Look at Alnylam Pharmaceuticals's Options Market Dynamics ↗

August 22, 2025

Via Benzinga

How Is The Market Feeling About Alnylam Pharmaceuticals? ↗

August 13, 2025

Via Benzinga

Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

August 13, 2025

Via Benzinga

Where Alnylam Pharmaceuticals Stands With Analysts ↗

August 07, 2025

Via Benzinga

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today ↗

August 04, 2025

Via Benzinga

Demystifying Alnylam Pharmaceuticals: Insights From 19 Analyst Reviews ↗

August 04, 2025

Via Benzinga

This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday ↗

August 04, 2025

Via Benzinga

Reddit, Wingstop, And Generac Are Among Top 10 Large Cap Gainers Last Week (July 28-August 1): Are The Others In Your Portfolio? ↗

August 03, 2025

Reddit, Wingstop, and Generac led large-cap gains last week on strong Q2 results and upbeat guidance across multiple sectors.

Via Benzinga

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance ↗

August 01, 2025

Alnylam sees strong Amvuttra uptake in ATTR-CM with $150 million revenue boost; analysts hike price targets following FDA approval and launch momentum.

Via Benzinga

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast ↗

July 31, 2025

Alnylam stock jumps after Q2 earnings beat and higher 2025 guidance, led by Amvuttra's rapid uptake and strong growth across the TTR and Rare franchises.

Via Benzinga

Topics Earnings

Roblox, Carvana, eBay, C.H. Robinson Worldwide, Huntington Ingalls Industries And Other Big Stocks Moving Higher On Thursday ↗

July 31, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.